Plantar Fasciitis - Pipeline Insight, 2024

This “Plantar Fasciitis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Plantar Fasciitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Plantar Fasciitis Understanding

Plantar Fasciitis: Overview

Plantar fasciitis is a one of the really common causes of heel pain. The plantar fascia is a weblike ligament which is thick and connects the heel to the front of the foot. It helps in walking as it acts as a shock absorber and also provides support to the arch of the foot. The ligament experiences a lot of wear and tear in everyday life causing the plantar fascia to become inflamed, which in turn leads to stiffness and heel pain.

Symptoms
Symptoms of plantar fasciitis are pain at the bottom of the foot near the heel, excessive pain after an activity or exercising, and pain when first few steps are taken after waking up in the moring, or after long periods of rest.

Diagnosis
Diagnosis of plantar fasciitis is made based on the physical examination and medical history. Commonly, no special tests are required but the doctor may suggest an MRI or X-ray to be sure of the cause of the pain.

Treatment
Majority of people suffering from plantar fasciitis recover in few months with conservative treatment which includes stretching, resting, and icing the painful area. Some medications such as naproxen sodium and ibuprofen may be prescribed for relieving the pain. Therapies, and special devices such as orthotics, physical therapies, and night splints may further help in relieving the symptoms. If conservative methods don’t work, then surgical procedures are taken help of such as the extracorporeal shock wave therapy, surgery, and ultrasonic tissue repair.

Plantar Fasciitis Emerging Drugs Chapters

This segment of the Plantar Fasciitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plantar Fasciitis Emerging Drugs

Micronized d HCAM: Mimedx Micronized d HCAM (dehydrated human amnion/chorion membrane tissue allografts), being developed by Mimedx, are in the phase III stage of drug development. This therapy is derived from the amniotic membrane, which is a placental tissue that is capable of supporting fetus development during pregnancy. The membrane comprises of extracellular matrix components such as fibronectin, collagen, and laminin along with various cytokines and growth factors. The graft is said to have regenerative properties, thereby being recommended to be used in the treatment of various orthopedic tissue injuriesincludingplantarfasciitis.

DAXI: Revance Therpaeutics Revance Therapeutics, DAXI, also called as Daxibotulinum toxin A, is in the phase II stage of drug development. The company aims to study the drug candidate for other neuromodulator conditions along with PlantarFasciitis.

Plantar Fasciitis: Therapeutic Assessment

This segment of the report provides insights about the different Plantar Fasciitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Plantar Fasciitis

There are approx. 3+ key companies which are developing the therapies for Plantar Fasciitis. The companies which have their Plantar Fasciitis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Mimedx and others.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Plantar Fasciitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plantar Fasciitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Plantar Fasciitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plantar Fasciitis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Plantar Fasciitis R&D. The therapies under development are focused on novel approaches to treat/improve Plantar Fasciitis.

Plantar Fasciitis Report Insights

• Plantar Fasciitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Plantar Fasciitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Plantar Fasciitis drugs?
• How many Plantar Fasciitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Plantar Fasciitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Plantar Fasciitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Plantar Fasciitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mimedx
• Revance Therapeutics

Key Products

• Micronized dHCAM
• DAXI

This product will be delivered within 2 business days.